TriangleNCT03154047 · REGISTRY CONDITION SEARCH
Study in Subjects With Light Chain (AL) Amyloidosis
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2019-03-26
The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Completed the End of Study Visit in Study NEOD001-201 2. Adequate bone marrow reserve, hepatic and renal function, as demonstrated by: * Absolute neutrophil count (ANC) ≥1.0 × 109/L * Platelet count ≥75 × 109/L * Hemoglobin ≥9 g/dL * Total bilirubin ≤2 × upper limit of normal (ULN) * Aspartate aminotransferase (AST) ≤3 × ULN * Alanine aminotransferase (ALT) ≤3 × ULN * Alkaline phosphatase (ALP) ≤5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone) * Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, or measured GFR ≥25 mL/min/1.73 m2 3. Systolic blood pressure 80-180 mmHg 4. Women of childbearing potential must have a negative pregnancy test during Screening and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration 5. Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration 6. Ability to understand and willingness to sign an informed consent form prior to initiation of any study procedures Exclusion Criteria: 1. Any new medical contraindication or clinically significant abnormality on physical, neurological, laboratory, vital signs, or electrocardiographic (ECG) examination (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular rate is controlled) that precludes continuation or initiation of treatment with NEOD001 or participation in the study 2. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject's ability to safely receive treatment or complete study assessments 3. Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit 4. Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area \<1.0 cm2) or severe congenital heart disease 5. ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following: * First degree atrioventricular (AV) block * Second degree AV block Type 1 (Mobitz Type 1/ Wenckebach type) * Right or left bundle branch block * Atrial fibrillation with a controlled ventricular rate (uncontrolled \[i.e., \>110 bpm\] ventricular rate is not allowed \[determined by an average of three beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG\]) 6. Has not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse Events \[CTCAE\] ≥Grade 2) from the clinically significant toxic effects of prior anticancer therapy. Exception: subjects who have received treatment with a proteasome inhibitor such as bortezomib may have CTCAE Grade 2 neuropathy. 7. Received any of the following within the specified time frame prior to the Month 1-Day 1 Visit: * Oral or IV antibiotics, antifungals, or antivirals within 1 week, with the exception of prophylactic oral agents. Note: In the event that a subject requires the chronic use of antivirals, Medical Monitor permission is required for entry into the study. * Hematopoietic growth factors, transfusions of blood or blood products within 1 week * Chemotherapy, radiotherapy, HDAC inhibitors, or other plasma cell directed therapy within 2 weeks * ASCT within 4 weeks (i.e., ASCT is allowed if it occurred before enrollment in Study NEOD001-201 or after completion of Study NEOD001-201 if it was at least 4 weeks before Month 1-Day 1 of this study) * Major surgery within 4 weeks (or within 2 weeks following consultation with and approval of Medical Monitor) * Planned organ transplant during the study * Any investigational agent, other than NEOD001, within 4 weeks * Any experimental imaging agent directed at amyloid within 2 weeks 8. Active malignancy with the exception of any of the following: * Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer * Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years * Low-risk prostate cancer with Gleason score \<7 and prostate-specific antigen \<10 mg/mL * Any other cancer from which the subject has been disease-free for ≥2 years 9. History of Grade ≥3 infusion-related adverse events (AEs) or hypersensitivity to NEOD001 10. History of severe allergy to any of the components of NEOD001 such as histidine/L-Histidine, Trehalose, or Polysorbate 20 11. Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infection 12. Women who are breastfeeding 13. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study 14. Unable or unwilling to adhere to the study-specified procedures and restrictions 15. Subject is under legal custodianship
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Open Label Study Drug NEOD001
- intervention Names
- Drug: NEOD001
- label
- Open label
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Open label
- description
- humanized monoclonal antibody
- name
- NEOD001
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 80
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
- measure
- Number of Participants With Adverse Events
- time Frame
- Each subject's study participation may have been up to 36 months or until the study was terminated
Full study description
- brief Summary
- The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
- detailed Description
- Global, multicenter, Phase 2b, open-label extension study of subjects with AL amyloidosis who had a hematologic response to first-line treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant \[ASCT\]) and completed Study NEOD001-201. Subjects in this study may receive concomitant chemotherapy. Subject screening will occur during the 28 days prior to the first administration of study drug, which may overlap with the last visit in Study NEOD001-201. If all eligibility requirements are met, the subject will be enrolled and Screening assessments will be completed. Study visits will occur every 28 days based on scheduling from Month 1 Day 1. A ±5-day window is allowed for visits starting after Month 1. Subjects who discontinue study drug before the End of Study Visit (EOS) should have an Early Treatment Discontinuation Visit 30 (±5) days after their final administration of study drug. Each subject's study participation may be up to 38 months or until the study is terminated, whichever occurs first. The study consists of a Screening Phase (1 month), Treatment Phase (36 months), and EOS Visit (30 \[±5\] days after the last dose).
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-7b69f6a089ab7a36ea72
- requested nct id
- NCT03154047
- primary nct id
- NCT03154047
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
- payload sha256
- 1f8f9e88d518637920ab73499a9d808a895ef4a980c3f2e70bb8e534f3382c27
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-7b69f6a089ab7a36ea72
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT03154047
- occurrences
- context exact
- NCT03154047
- end
- 11
- exact text
- NCT03154047
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-001.json
- source file sha256
- f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
- source json pointer
- /studies/16/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 1ba6685c36ca0d55e7860367efa77f6f049d9febf618ff8c79d2698265a6ee95
Preserved source evidence · Not medical advice